Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer|
S-Y Ung, B.
|Citation:||Pathology, 2023; 55(1):40-51|
|Carmela Martini … Adrian J. Esterman … Kim L. Moretti, Lisa M. Butler … Douglas A. Brooks|
|Abstract:||Diagnosis and assessment of patients with prostate cancer is dependent on accurate interpretation and grading of histopathology. However, morphology does not necessarily reflect the complex biological changes occurring in prostate cancer disease progression, and current biomarkers have demonstrated limited clinical utility in patient assessment. This study aimed to develop biomarkers that accurately define prostate cancer biology by distinguishing specific pathological features that enable reliable interpretation of pathology for accurate Gleason grading of patients. Online gene expression databases were interrogated and a pathogenic pathway for prostate cancer was identified. The protein expression of key genes in the pathway, including adaptor protein containing a pleckstrin homology (PH) domain, phosphotyrosine-binding (PTB) domain, and leucine zipper motif 1 (Appl1), Sortilin and Syndecan-1, was examined by immunohistochemistry (IHC) in a pilot study of 29 patients with prostate cancer, using monoclonal antibodies designed against unique epitopes. Appl1, Sortilin, and Syndecan-1 expression was first assessed in a tissue microarray cohort of 112 patient samples, demonstrating that the monoclonal antibodies clearly illustrate gland morphologies. To determine the impact of a novel IHC-assisted interpretation (the utility of Appl1, Sortilin, and Syndecan-1 labelling as a panel) of Gleason grading, versus standard haematoxylin and eosin (H&E) Gleason grade assignment, a radical prostatectomy sample cohort comprising 114 patients was assessed. In comparison to H&E, the utility of the biomarker panel reduced subjectivity in interpretation of prostate cancer tissue morphology and improved the reliability of pathology assessment, resulting in Gleason grade redistribution for 41% of patient samples. Importantly, for equivocal IHC-assisted labelling and H&E staining results, the cancer morphology interpretation could be more accurately applied upon re-review of the H&E tissue sections. This study addresses a key issue in the field of prostate cancer pathology by presenting a novel combination of three biomarkers and has the potential to transform clinical pathology practice by standardising the interpretation of the tissue morphology.|
|Keywords:||Prostate cancer pathology|
|Description:||Available online 20 August 2022.|
|Rights:||© 2022 The Authors. Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).|
|Appears in Collections:||Medicine publications|
South Australian Immunogenomics Cancer Institute (SAIGENCI) publications
Files in This Item:
|hdl_136970.pdf||Published version||6.03 MB||Adobe PDF||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.